IMM leads host-microbiome interaction research in EU BIOMAP
Atopic dermatitis and psoriasis affect more than 300 million people worldwide and are highly variable in terms of onset, severity, progression over time and response to treatment. BIOMAP will examine the causes and mechanisms of these conditions by identifying the biomarkers responsible for the variation in disease outcome.
The BIOMAP consortium includes 31 partners from 12 countries and the budget is 20.8 M€. BIOMAP is funded via IMI2 Joint Undertaking (JU). The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
The unit of system toxicology at IMM is the leader of the work-package investigating host-microbiome interaction. Microbial factors are triggers of atopic dermatitis and psoriasis. Microbes might even be among the main causative factors of atopic dermatitis manifestation indicating potential for diagnostic and therapeutic exploitation.
IMM will investigate microbial patterns linked to atopic dermatitis or psoriasis, and potential disease subtypes based on microbial heterogeneity. Furthermore, normal variability across time scales due to disease- and disease-activity related changes, and host molecular constituents related to normal and pathological shifts will be analyzed.